Research & Literature

Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report.

Sahraian MA, Moghadasi AN, Owji M, et al.

Journal of medical case reports 2015; (9()):137 doi:10.1186/s13256-015-0613-9.

International consensus diagnostic criteria for neuromyelitis optica spectrum disorders.

Wingerchuk DM, Banwell B, Bennett JL, et al.

Neurology 2015; (85(2)):177-89 doi:10.1212/WNL.0000000000001729.

Multiple sclerosis and neuromyelitis optica spectrum disorders: some similarities in two distinct diseases.

Yokote H, Mizusawa H

Neural regeneration research 2016; (11(3)):410-1 doi:10.4103/1673-5374.179048.

The role of AQP4 in neuromyelitis optica: More answers, more questions.

Yang X, Ransom BR, Ma JF

Journal of neuroimmunology 2016; (298()):63-70.

Catastrophic relapses following initiation of dimethyl fumarate in two patients with neuromyelitis optica spectrum disorder.

Yamout BI, Beaini S, Zeineddine MM, Akkawi N

Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(9)):1297-1300 doi:10.1177/1352458517694086.

Unexpected exacerbations following initiation of disease-modifying drugs in neuromyelitis optica spectrum disorder: Which factor is responsible, anti-aquaporin 4 antibodies, B cells, Th1 cells, Th2 cells, Th17 cells, or others?

Kira JI

Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(9)):1300-1302 doi:10.1177/1352458517703803.

Autonomic Dysregulation, Cognitive Impairment, and Symptoms of Psychosis as an Unusual Presentation in an Anti-Aquaporin 4-Positive Patient.

Ruiter AM, Meilof JF, Somanje-Bolweg RRJ, et al.

Case reports in neurology 2017; (9(1)):12-16 doi:10.1159/000455942.

Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes.

Wang Z, Guo W, Liu Y, et al.

Brain, behavior, and immunity 2017; (65()):173-182 doi:10.1016/j.bbi.2017.04.023.

Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders.

Bonnan M, Valentino R, Debeugny S, et al.

Journal of neurology, neurosurgery, and psychiatry 2018; (89(4)):346-351 doi:10.1136/jnnp-2017-316286.

Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review.

Wang KY, Chetta J, Bains P, et al.

The British journal of radiology 2018; (91(1086)):20170690 doi:10.1259/bjr.20170690.

Investigational drugs in development to prevent neuromyelitis optica relapses.

Paul F, Murphy O, Pardo S, Levy M

Expert opinion on investigational drugs 2018; (27(3)):265-271 doi:10.1080/13543784.2018.1443077.

Neuromyelitis optica spectrum disorder in the elderly associated with bronchiolitis obliterans organizing pneumonia.

Ruisanchez Nieva A, Sanchez Menoyo JL, Escalza Cortina I, et al.

Neurology. Clinical practice 2017; (7(5)):404-406 doi:10.1212/CPJ.0000000000000336.

Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis.

Ma X, Zhang L, Huang D, et al.

Journal of magnetic resonance imaging : JMRI 2019; (49(4)):1113-1121 doi:10.1002/jmri.26287.

Area postrema syndrome: A short history of a pearl in demyelinating diseases.

Camara-Lemarroy CR, Burton JM

Multiple sclerosis (Houndmills, Basingstoke, England) 2019; (25(3)):325-329 doi:10.1177/1352458518813105.

Outcomes from acute attacks of neuromyelitis optica spectrum disorder correlate with severity of attack, age and delay to treatment.

Banerjee A, Ng J, Coleman J, et al.

Multiple sclerosis and related disorders 2019; (28()):60-63 doi:10.1016/j.msard.2018.12.010.

Do Myelin Oligodendrocyte Glycoprotein Antibodies Represent a Distinct Syndrome?

Chen JJ, Fraser CL

Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2019; (39(3)):416-423 doi:10.1097/WNO.0000000000000779.

Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder.

Pittock SJ, Berthele A, Fujihara K, et al.

The New England journal of medicine 2019; (381(7)):614-625 doi:10.1056/NEJMoa1900866.

AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD.

Prain K, Woodhall M, Vincent A, et al.

Frontiers in neurology 2019; (10()):1028 doi:10.3389/fneur.2019.01028.

A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX.

Songthammawat T, Srisupa-Olan T, Siritho S, et al.

Multiple sclerosis and related disorders 2020; (38()):101506 doi:10.1016/j.msard.2019.101506.

Atypical Pediatric Demyelinating Diseases of the Central Nervous System.

Troxell RM, Christy A

Current neurology and neuroscience reports 2019; (19(12)):95 doi:10.1007/s11910-019-1015-y.

Two Cases of Very-Late-Onset Neuromyelitis Optica Spectrum Disorder (NMOSD) in Patients over the Age of 80.

Fujiwara S, Manabe Y, Morihara R, et al.

Case reports in neurology 2020; (12(1)):13-17 doi:10.1159/000505231.

Precision therapy for neuromyelitis optica spectrum disorder: A retrospective analysis of the use of class-switched memory B-cells for individualised rituximab dosing schedules.

Trewin BP, Adelstein S, Spies JM, et al.

Multiple sclerosis and related disorders 2020; (43()):102175 doi:10.1016/j.msard.2020.102175.

Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.

Gomez-Figueroa E, Noriega-Morales G, Casallas-Vanegas A, et al.

Clinical neurology and neurosurgery 2020; (196()):106007 doi:10.1016/j.clineuro.2020.106007.

Eculizumab impairs Neisseria meningitidis serogroup B killing in whole blood despite 4CMenB vaccination of PNH patients.

Langereis JD, van den Broek B, Franssen S, et al.

Blood advances 2020; (4(15)):3615-3620 doi:10.1182/bloodadvances.2020002497.

Effect of plasma exchange in neuromyelitis optica spectrum disorder: A systematic review and meta-analysis.

Kosiyakul P, Songwisit S, Ungprasert P, et al.

Annals of clinical and translational neurology 2020; (7(11)):2094-2102 doi:10.1002/acn3.51203.

Recent progress in maintenance treatment of neuromyelitis optica spectrum disorder.

Holmøy T, Høglund RA, Illes Z, et al.

Journal of neurology 2021; (268(12)):4522-4536 doi:10.1007/s00415-020-10235-5.

Rapid Administration of High-Dose Intravenous Methylprednisolone Improves Visual Outcomes After Optic Neuritis in Patients With AQP4-IgG-Positive NMOSD.

Akaishi T, Takeshita T, Himori N, et al.

Frontiers in neurology 2020; (11()):932 doi:10.3389/fneur.2020.00932.

Central Sleep Apnea Syndrome Can Complicate Neuromyelitis Optica Spectrum Disorder: A Case Report.

Morelli C, Aeby A, Scaillet S, et al.

Frontiers in pediatrics 2020; (8()):547474 doi:10.3389/fped.2020.547474.

New therapies for neuromyelitis optica spectrum disorder.

Levy M, Fujihara K, Palace J

The Lancet. Neurology 2021; (20(1)):60-67 doi:10.1016/S1474-4422(20)30392-6.

Neuromyelitis optica spectrum disorders.

Paul S, Mondal GP, Bhattacharyya R, et al.

Journal of the neurological sciences 2021; (420()):117225 doi:10.1016/j.jns.2020.117225.

Timing of plasma exchange for neuromyelitis optica spectrum disorders: A meta-analysis.

Huang X, Wu J, Xiao Y, Zhang Y

Multiple sclerosis and related disorders 2021; (48()):102709 doi:10.1016/j.msard.2020.102709.

Optimal management of neuromyelitis optica spectrum disorder with aquaporin-4 antibody by oral prednisolone maintenance therapy.

Takai Y, Kuroda H, Misu T, et al.

Multiple sclerosis and related disorders 2021; (49()):102750 doi:10.1016/j.msard.2021.102750.

Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD.

Wingerchuk DM, Fujihara K, Palace J, et al.

Annals of neurology 2021; (89(6)):1088-1098 doi:10.1002/ana.26049.

Drug Treatment of Neuromyelitis Optica Spectrum Disorders: Out with the Old, in with the New?

Held F, Klein AK, Berthele A

ImmunoTargets and therapy 2021; (10()):87-101 doi:10.2147/ITT.S287652.

Emerging drugs for the treatment of adult MOG-IgG-associated diseases.

Carnero Contentti E, Marrodan M, Correale J

Expert opinion on emerging drugs 2021; (26(2)):75-78 doi:10.1080/14728214.2021.1919082.

PLEX: the best first-line treatment in nmosd attacks experience at a single center in Colombia.

Restrepo-Aristizábal C, Giraldo LM, Giraldo YM, et al.

Heliyon 2021; (7(4)):e06811 doi:10.1016/j.heliyon.2021.e06811.

AQP4-IgG positive paraneoplastic NMOSD: A case report and review.

Ding M, Lang Y, Cui L

Brain and behavior 2021; (11(10)):e2282 doi:10.1002/brb3.2282.

Hope for patients with neuromyelitis optica spectrum disorders - from mechanisms to trials.

Pittock SJ, Zekeridou A, Weinshenker BG

Nature reviews. Neurology 2021; (17(12)):759-773 doi:10.1038/s41582-021-00568-8.

Spectrum of sublytic astrocytopathy in neuromyelitis optica.

Guo Y, Lennon VA, Parisi JE, et al.

Brain : a journal of neurology 2022; (145(4)):1379-1390 doi:10.1093/brain/awab394.

Late onset neuromyelitis optica spectrum disorder with anti-aquaporin 4 and anti-myelin oligodendrocyte glycoprotein antibodies.

Wang L, Tan H, Huang W, et al.

European journal of neurology 2022; (29(4)):1128-1135 doi:10.1111/ene.15239.

Treatment regimens for neuromyelitis optica spectrum disorder attacks: a retrospective cohort study.

Demuth S, Guillaume M, Bourre B, et al.

Journal of neuroinflammation 2022; (19(1)):62 doi:10.1186/s12974-022-02420-2.

Seronegative neuromyelitis optica spectrum disorder with longitudinally extending transverse myelitis and optic neuritis: A case report.

Khadka B, Bhattarai AM, Dhakal B, et al.

Annals of medicine and surgery (2012) 2022; (78()):103757 doi:10.1016/j.amsu.2022.103757.

Immunobiology of neuromyelitis optica spectrum disorders.

Mora Cuervo DL, Hansel G, Sato DK

Current opinion in neurobiology 2022; (76()):102618 doi:10.1016/j.conb.2022.102618.

Frequency of NMOSD misdiagnosis in a cohort from Latin America: Impact and evaluation of different contributors.

Carnero Contentti E, López PA, Criniti J, et al.

Multiple sclerosis (Houndmills, Basingstoke, England) 2023; (29(2)):277-286 doi:10.1177/13524585221136259.

Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents.

Paolilo RB, Paz JAD, Apóstolos-Pereira SL, et al.

Arquivos de neuro-psiquiatria 2023; (81(2)):201-211 doi:10.1055/s-0043-1761432.

Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: a phase 3, multicentre, open-label, randomised controlled trial.

Annane D, Pittock SJ, Kulkarni HS, et al.

The Lancet. Respiratory medicine 2023; (11(12)):1051-1063 doi:10.1016/S2213-2600(23)00082-6.

Painful tonic spasms in a patient with neuromyelitis optica spectrum disorder: A case report.

Aryal R, Homagian S, Shrestha S, et al.

SAGE open medical case reports 2023; (11()):2050313X231167937 doi:10.1177/2050313X231167937.

Case Report: Severe rebound after withdrawal of fingolimod in a patient with neuromyelitis optica spectrum disorder.

Lin W, Chou CH, Yang FC, et al.

Frontiers in immunology 2023; (14()):1115120 doi:10.3389/fimmu.2023.1115120.

Associations between neuromyelitis optica spectrum disorder, Sjögren's syndrome, and conditions with electrolyte disturbances.

Akaishi T, Tarasawa K, Matsumoto Y, et al.

Journal of the neurological sciences 2023; (452()):120742 doi:10.1016/j.jns.2023.120742.

Advances in the long-term treatment of neuromyelitis optica spectrum disorder.

Anderson M, Levy M

Journal of central nervous system disease 2024; (16()):11795735241231094 doi:10.1177/11795735241231094.

Safety Profile of Monoclonal Antibodies and Subsequent Drug Developments in the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mallenahalli Neeekantappa V, Kamath A, Bharathi Rajaduraivelpandian P

Medicina (Kaunas, Lithuania) 2024; (60(3)) doi:10.3390/medicina60030379.

Visual Function Improvement after Plasma Exchange Therapy for Acute Optic Neuritis in Neuromyelitis Optica Spectrum Disorders: Case Series and Review.

Iancu R, Pirvulescu R, Anton N, et al.

Diagnostics (Basel, Switzerland) 2024; (14(9)) doi:10.3390/diagnostics14090863.

The correlation between rituximab dose reduction and acute relapses of neuromyelitis optica spectrum disorder, lessons from COVID-19 epidemic.

Ashtari F, Mehdipour R, Asgari M, Ghalamkari A

Multiple sclerosis and related disorders 2024; (92()):105940 doi:10.1016/j.msard.2024.105940.

An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder.

Balaban DT, Levy M, Borrow R, Anderson MR

Expert opinion on biological therapy 2024; (24(11)):1193-1198 doi:10.1080/14712598.2024.2423002.

Satralizumab treatment in patients with AQP4-IgG-seropositive neuromyelitis optica spectrum disorder after rituximab treatment: A case series.

Abboud H, Steingo B, Vargas D, et al.

Journal of neuroimmunology 2025; (403()):578585 doi:10.1016/j.jneuroim.2025.578585.

Intractable Vomiting and Hiccups: An Atypical Presentation of Neuromyelitis Optica Spectrum Disorder.

Sarna MK, Setia M, Rijhwani P, et al.

The Journal of the Association of Physicians of India 2025; (73(4)):93-96 doi:10.59556/japi.73.0911.

Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Long-term Follow-up and Therapeutic Challenges in a Treatment-Resistant Case.

Yetkin MF, Benli Ş, Mirza M

Journal of child neurology 2025; (40(8)):704-707 doi:10.1177/08830738251340278.

Satralizumab Ameliorates Refractory Central Neuropathic Pain and Painful Tonic Spasms in Neuromyelitis Optica Spectrum Disorder: A Case Report.

Matsuo J, Nakahara K, Hara Y, Ueda M

Cureus 2025; (17(6)):e86335 doi:10.7759/cureus.86335.

Eculizumab as a rescue therapy in acute-phase aquaporin-4 (AQP4) antibody-positive neuromyelitis optica spectrum disorder.

Zeng K, Chen W, Lin A

Journal of neurology 2026; (273(1)):73.

Complement Inhibition for Acute Neuromyelitis Optica Spectrum Disorder Attacks: Insights From an International Case Series.

Rommer PS, Jiang W, Nolte JP, et al.

Neurology(R) neuroimmunology & neuroinflammation 2026; (13(2)):e200548 doi:10.1212/NXI.0000000000200548.

Progress in the Treatment of Neuromyelitis Optica Spectrum Disorder: From Pathogenic Insights to Biologics.

Ikeguchi R, Shimizu Y, Todo K

Internal medicine (Tokyo, Japan) 2026; doi:10.2169/internalmedicine.6772-25.

Endothelial cell-secreted SPARC suppresses astrocytic CD59 expression and promotes astrocytopathy in a mouse model of neuromyelitis optica spectrum disorders.

Cui T, Gong Y, Wang Z, et al.

Nature communications 2026; (17(1)).